Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 2/3 1

Status

Recruiting 14Not yet recruiting 9Active not recruiting 5Completed 3

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 5

Conditions

Breast Neoplasms 3HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane 1Breast Cancer Female 1

Interventions

pembrolizumab 374Carboplatin 276Specimen Handling 265Nivolumab 252Magnetic Resonance Spectroscopy 244Cyclophosphamide 240Cisplatin 213Paclitaxel 206Radiotherapy 195Biopsy 171Gemcitabine 155Dexamethasone 148durvalumab 143atezolizumab 126Rituximab 120Doxorubicin 115Bevacizumab 114Lenalidomide 113Ipilimumab 111Radiation 109Docetaxel 103Pemetrexed 102Etoposide 101fludarabine 97venetoclax 95Fluorouracil 92Capecitabine 92Radiosurgery 90Prednisone 89Oxaliplatin 89

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Active not recruiting × pyrotinib × 1 year × Clear all
NCT06144944 2026-01-30

Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 3 Active not recruiting
160 enrolled
Breast

Breast Neoplasms

NCT04290793 2026-01-07

Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer

Hebei Medical University Fourth Hospital

Phase 2/3 Active not recruiting
113 enrolled
Breast

Breast Neoplasms

NCT04872985 2026-01-06

Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2 Active not recruiting
140 enrolled
Breast

Breast Neoplasms

NCT04126525 2025-09-11

NeoATP

RenJi Hospital

Phase 2 Active not recruiting
53 enrolled
Breast

Breast Cancer Female

NCT05424835 2025-08-22

A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Active not recruiting
381 enrolled
Breast

HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane

Data powered by HemOnc (CC BY 4.0) Colophon âš¡